Related Experiment Video

Updated: Jun 3, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Atrial fibrillation: pharmacological therapy

Chinmay Patel, Mohammed Salahuddin, Andria Jones

    Current Problems in Cardiology
    |March 12, 2011
    PubMed

    Insights

    Atrial fibrillation (AF) management focuses on symptom relief and stroke prevention. Both rate control and rhythm control strategies are effective, with specific approaches favored based on patient factors and clinical trial evidence.

    Area of Science:

    • Cardiology
    • Clinical Medicine

    Background:

    • Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia.
    • AF is an independent predictor of mortality and morbidity.
    • AF management aims to alleviate symptoms and prevent stroke.

    Purpose of the Study:

    • To discuss the relative merits of rate control versus rhythm control strategies for atrial fibrillation.
    • To highlight clinical trial evidence supporting each treatment approach.

    Main Methods:

    • Review of clinical trial data on AF treatment strategies.
    • Discussion of anticoagulation with warfarin.
    • Evaluation of rate control using atrioventricular nodal blocking agents.
    • Assessment of rhythm control using antiarrhythmic drugs.

    Main Results:

    • Warfarin anticoagulation is unequivocally proven for stroke prevention.
    • Rate control is a practical and often optimal strategy.
    • Rhythm control may be ideal for specific patient groups (young, symptomatic, new-onset AF).

    Conclusions:

    • Both rate and rhythm control strategies have demonstrated clinical benefits in managing atrial fibrillation.
    • Treatment choice should be individualized based on patient characteristics and available evidence.

    More Related Videos

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

    Published on: February 26, 2013

    High-Resolution Endocardial and Epicardial Optical Mapping in a Sheep Model of Stretch-Induced Atrial Fibrillation09:17

    High-Resolution Endocardial and Epicardial Optical Mapping in a Sheep Model of Stretch-Induced Atrial Fibrillation

    Published on: July 29, 2011

    Related Concept Videos

    Dysrhythmias VI: Management of Dysrhythmias01:25

    Dysrhythmias VI: Management of Dysrhythmias

    Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
    ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

    ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

    Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

    Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
    Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
    Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

    Cardiopulmonary Resuscitation IV: Pharmacological Management

    Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...